-1.png?width=1169&height=277&name=Inovia%20Logo%20Dark%20(1)-1.png)
Why one integrated evidence plan has to satisfy payer, regulator and prescriber at once, and how the comparator choice is the fork where it usually breaks.
How an integrated evidence plan aligns evidence generation across functions to de-risk the path to regulatory success.
What the Inflation Reduction Act's pricing and negotiation rules mean for how drug development programmes are designed and prioritised.
The four early decisions that expire once the protocol locks, and why HEOR has to be in the integrated evidence plan from day one.
How to choose a pivotal-trial endpoint that clears both the regulator and the payer, so you avoid a second invoice at reimbursement.
Five axes to grade your evidence the way an HTA reviewer or payer will, so you find the gaps before they do.
